Haleon PLC (GB:HLN)
LSE:HLN
Want to see GB:HLN full AI Analyst Report?
HLN Stock Chart & Stats
358.60 p
2.70 p(0.71%)
At close: 4:00 PM EST
358.60 p
2.70 p(0.71%)
Day’s Range― - ―
52-Week Range274.40 p - 416.10 p
Previous CloseN/A
Volume4.86M
Average Volume (3M)23.77M
Market Cap
£29.49B
Enterprise Value37.08B
Total Cash (Recent Filing)£676.00M
Total Debt (Recent Filing)£8.54B
Price to Earnings (P/E)29.4
Beta0.43
Next Earnings
Jul 30, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.16
Shares Outstanding8,830,688,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£426.67Price Target Upside18.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.39B
Bulls Say, Bears Say
Bulls Say
Consistent Free Cash Flow GenerationHaleon consistently converts earnings into strong operating and free cash flow, providing durable internal funding for A&P, R&D, debt reduction and capital allocation. Reliable FCF supports reinvestment and balance-sheet resilience over the medium term.
Strong Oral Health Brands And Emerging Market ExecutionWell-known oral-health brands and robust emerging-market traction provide structural growth engines. Brand equity and successful low-price and e‑commerce strategies in India/China drive volume and margin resilience independent of developed-market cycles.
Margin Improvement And Structural Cost SavingsMeaningful gross-margin uplift and a defined $175–$200m savings program reflect structural efficiency gains from supply‑chain simplification and OEE improvement. These durable savings create capacity to reinvest and support medium‑term margin expansion.
Bears Say
Low Volume Growth Versus PeersSubpar volume expansion constrains long‑term top‑line compounding and implies reliance on pricing/mix. Sustained low volumes challenge market-share gains, limit operating leverage benefits, and increase sensitivity to competitive private‑label pressure.
Category And U.S. Demand WeaknessesPersistent cold & flu softness and digestive‑health pressure in the U.S. hit a key market and categories with structural headwinds. Repeated weak seasons and retailer destocking raise the risk that near‑term demand shocks become longer‑lasting revenue drags.
Leverage Elevated Versus Pre‑spin LevelsAlthough debt declined in 2025, leverage sits materially above earlier years, reducing financial flexibility. Elevated leverage can constrain strategic spending, increase interest vulnerability in stress, and limits optionality for large M&A or heavy capex cycles.
Haleon PLC News
HLN FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest share price was 274.40 p and its highest was 416.10 p in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is £29.49B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Feb 25, 2026. The company reported 0.048 p earnings per share for the quarter, beating the consensus estimate of 0.046 p by 0.002 p.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC pays a Quarterly dividend of 4.9 p which represents an annual dividend yield of 1.51%. See more information on Haleon PLC dividends here
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.05.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,830,688,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of 0.048 p in its last earnings report, beating expectations of 0.046 p. Following the earnings report the stock price went down -6.852%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in GB:HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£426.67 (18.98% Upside)
£426.67 (18.98% Upside)
Blogger Sentiment
Bullish
GB:HLN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.91%
12-Months-Change
Fundamentals
Return on Equity
6.43%
Trailing 12-Months
Asset Growth
-4.91%
Trailing 12-Months
Company Description
Haleon PLC
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
HLN Stock 12 Month Forecast
Average Price Target
426.67 p
▲(18.98% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---